Tanja Tomić

Ms. Tanja Tomić

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
TTTanja Tomić
Tanja Tomić
DTDavor Tomić
Davor Tomić
MVMartina Vukoja
Martina Vukoja
MKMarija Kraljevic
Marija Kraljevic
ILIvona Ljevak
Ivona Ljevak
VSVioleta Soljic
Violeta Soljic
While clear cell renal cell carcinoma (ccRCC) is curable, advanced metastatic (mRCC) remains a clinical challenge. We analyzed clinical, pathohistological, and molecular data (Receptor Interacting Protein 5—RIP5 and Vestigial Like Family Member 4—VGLL4 expression) of 55 mRCC patients treated with first-line treatment with sunitinib. The trend of linear increase in the protein expression of RIP5 was observed with the progression of tumor grade. Overall, 80% of RIP5-positive cells were in the control kidneys and high-grade mRCC. On the contrary, RIP5 displayed low expression in grade 2 mRCC (5.63%). The trend of linear decrease in the expression of VGLL4 was observed with the progression of tumor grade. The highest protein expression of VGLL4 was observed in grade 2 (87.82%) in comparison to grade 3 and 4 and control. High expression of RIP5 mRNA was associated with longer first-line overall survival and longer progression-free survival in mRCC. In addition, a high VGLL4 mRNA expression showed better overall survival in patients with ccRCC. In conclusion, high mRNA expression of RIP5 and VGLL4 are important markers of better survival rates in mRCC patients.

30 November 2023 in Zdravstveni glasnik
Verified
Journal Article
Closed access
TTTanja Tomić
Tanja Tomić
AIAnita Ivanković
Anita Ivanković